The Latest in Medical Cannabis Research: Fall 2018
The third quarter of this year was full big headlines for the cannabis industry. Epidiolex became the first cannabis-based medicine to gain FDA-approval in the United States, Coca-Cola and Budweiser are preparing to jump into the cannabis market, and cannabis companies are causing waves in the stock market. All of this excitement is enhanced by the groundbreaking research studies that deepen our understanding of cannabis’ vast potential to improve our health and wellness. Here are five of the most exciting scientific studies from this quarter. Read more
Cannabis Businesses Owned by Women in California
Female cannabis consumers are entering the legalized market in droves, looking for products designed specifically for their needs, whether it be eye-catching, colorful prerolls, vape pens that soothe anxiety, edibles that relieve PMS, topical lotions that nourish skin, or bath salts that improve sleep. Read more
Cannabis short sellers rake in over $450 million in two days in pot stock slide
Cannabis short sellers made over $450 million on the first two days of the week, cutting nearly a third off their year-to-date losses, according to data from financial analytics firm S3 Partners. Pot stocks fell for six consecutive trading days beginning Oct. 16, the day before Canada legalized recreational marijuana. The BI Canada Cannabis Competitive Peers index tumbled 21 per cent from then through Tuesday’s close, and the Horizons Marijuana Life Sciences Index ETF, the largest pot exchange-traded fund, lost 20 percent to its lowest level in two months. Read more
Candidates for Illinois governor are split over marijuana legalization despite popular support
In supporting marijuana legalization, Illinois gubernatorial challenger J.B. Pritzker could usher in a change that affects everything from criminal justice to public health to the economy if he’s elected. In coming out against recreational use of cannabis, incumbent Gov. Bruce Rauner may appeal to his base, while finding himself on the less popular side of the issue. Read more
MedMen Generates $20.6 Million Revenue in Fiscal Q4
Robust asset base, balance sheet strength and large talent pool lay foundation for continued growth. Read more
Cannabis Stocks Are Plunging – Time to Sell?
So what were you thinking, getting into these high-beta stocks? If you’re not familiar with the term “high-beta,” it refers to stocks that are expected to be more volatile than the average. Of course, given the sell-offs we’ve been seeing across the broader market, such a term might not mean much at all in our current environment. Read more
The risk of loss in the trading of stocks, options, futures, forex, foreign equities, and bonds can be substantial and is not suitable for all investors. Trading on margin or the use of leverage is not suitable for all investors and losses exceeding your initial deposit is possible. Supporting documentation is available upon request. Trading futures, options on futures, and FX involves substantial risk of loss and is not suitable for all investors. Carefully consider whether trading is suitable for you in light of your circumstances, knowledge, and financial resources and only risk capital should be used. Opinions, market data, and recommendations are subject to change at any time. The lower the margin used the higher the leverage and therefore increases your risk. Past performance is not necessarily indicative of future results.